Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment

Thyroid Cancer Clinical Trial

Official title:

Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03624751
• Other study ID #: CE18104A
• Status: Recruiting
• Start date: June 30, 2018
• Est. completion date: June 30, 2030

Study information

• Verified date: August 2018
• Source: Taichung Veterans General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.

Description:

1. Objective： To observe the difference between Thyogen® injection or Eltroxin® withdrawal on metabolic profile.

2. Background and method:： The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.

Inclusion ： Patient number: 500人

Inclusion criteria :

1. Patients with diagnosis of thyroid cancer。

2. Patients who need radioiodine therapy or scan。

Exclusion criteria:

1. Patients cannot cooperate with blood test.。

2. Patients cannot cooperate with radioiodine therapy。 Study design： Prospective, observational study。

Method： We will collect 20cc blood and 20 cc urine before and after radioiodine therapy during each visit (total 3 visits) and check lipid profiles, glucose profiles and inflammation markers. We will compare the difference between results of patients undergoing Thyrogen® injection and Eltroxin® withdrawal.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: June 30, 2030
• Est. primary completion date: June 30, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with diagnosis of thyroid cancer?

2. Patients who need radioiodine therapy or scan?

Exclusion Criteria:

1. Patients cannot cooperate with blood test.?

2. Patients cannot cooperate with radioiodine therapy?

Related Conditions & MeSH terms

• Thyroid Cancer
• Thyroid Diseases
• Thyroid Neoplasms

Intervention

Radiation:
• radioiodine
Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan.

Locations

Country	Name	City	State
Taiwan	Division of Endocrinology and Metabolism in Taichung Veterans General Hospital	Taichung

Sponsors (1)

Lead Sponsor	Collaborator
Taichung Veterans General Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Zung's Self-reported depression scale	Depression symtpoms	1 month
Secondary	Brain-derived neurotrophic factor	BDNF	1 month
Secondary	orexin	An associated factor for depression	1 month
Secondary	Body composition	Fat component percentage to lean mass percentage ratio	1 months
Secondary	VCAM-1	adhesion molecules	1 months
Secondary	CRP	inflammation marker	1 months
Secondary	Metabolic syndrome	The number of conponents for metabolic syndrome	1 months